|
Volumn 20, Issue 3, 2015, Pages 245-246
|
Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors
c
SANOFI
(United States)
|
Author keywords
[No Author keywords available]
|
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
MITOGEN ACTIVATED PROTEIN KINASE;
PHOSPHATIDYLINOSITOL 3 KINASE;
PILARALISIB;
ANTINEOPLASTIC AGENT;
QUINAZOLINE DERIVATIVE;
QUINOXALINE DERIVATIVE;
SULFONAMIDE;
ADVANCED CANCER;
AREA UNDER THE CURVE;
ARTICLE;
ASTHENIA;
CANCER CHEMOTHERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CLINICAL ARTICLE;
DECREASED APPETITE;
DIARRHEA;
DRESS SYNDROME;
DRUG DOSE ESCALATION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
ENZYME INHIBITION;
FATIGUE;
FOLLICULITIS;
GENE MUTATION;
HUMAN;
MAXIMUM TOLERATED DOSE;
NAUSEA AND VOMITING;
NON SMALL CELL LUNG CANCER;
PHARMACODYNAMICS;
PHARMACOKINETIC ASSAY;
PHASE 1 CLINICAL TRIAL;
PLASMA CONCENTRATION-TIME CURVE;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RASH;
SOLID TUMOR;
SYSTEMIC DISEASE;
THROMBUS;
TREATMENT RESPONSE;
ANTAGONISTS AND INHIBITORS;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIAL;
DOSE RESPONSE;
FEMALE;
LUNG NEOPLASMS;
MALE;
TREATMENT OUTCOME;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, NON-SMALL-CELL LUNG;
DOSE-RESPONSE RELATIONSHIP, DRUG;
ERLOTINIB HYDROCHLORIDE;
FEMALE;
HUMANS;
LUNG NEOPLASMS;
MALE;
PHOSPHATIDYLINOSITOL 3-KINASE;
QUINAZOLINES;
QUINOXALINES;
SULFONAMIDES;
TREATMENT OUTCOME;
|
EID: 84925409338
PISSN: 10837159
EISSN: 1549490X
Source Type: Journal
DOI: 10.1634/theoncologist.2014-0449 Document Type: Article |
Times cited : (31)
|
References (0)
|